On 6th September 2022, the Azerbaijan Thalassemia Middle and BGI held a digital signing ceremony to seal a Collaboration Settlement. The partnership goals to enhance thalassemia screening in Azerbaijan by genetic expertise.
In early 2021, in event of the “Prevention and Management of International Haemoglobinopathies” announcement, BGI Poverty Prevention and Management Panel clearly acknowledged they search to export China’s superior applied sciences for thalassemia to ‘Belt and Street Initiative’ international locations, to collectively obtain complete thalassemia management within the international group.
In April 2022, BGI’s wholly-owned subsidiary, Huada Biotechnology (Wuhan) Co., Ltd, obtained the medical gadget registration certificates from the Nationwide Drug Administration for its alpha and beta thalassemia gene detection package (combining probe anchored polymerization sequencing methodology).
This settlement was signed by Dr. Valeh Hüseynov, the Government Director of Nationwide Hematology and Transfusiology Middle, Dr. Agha Rza Aghayev, the supervisor of Azerbaijan’s medical genetics division, and Mr. Jeremy Cao, the Vice President of BGI IntDx. The 2 organizations have entered a strategic partnership and can work collectively for a thalassemia research analysis mission within the nation.
Dr Agha Rza Aghayev, Azerbaijan’s medical genetics division supervisor, had the next to say: “Thanks BGI for help and collaboration, I hope this analysis program will assist us to construct an efficient and well-designed methodology for screening Thalassemia.”
Azerbaijan is among the international locations with the very best prevalence price of thalassemia. Our thalassemia gene detection testing combines cutting-edge excessive throughput sequencing platform and benefits of low value and complete detection. It helps scientific analysis partnership in methodology comparability, enhances new expertise collaboration within the scientific testing and discover the screening of thalassemia in Azerbaijan. BGI additionally has a world hemoglobinopathy basis specializing in preventing thalassemia worldwide, our objective is making the world a greater place with out this illness. BGI subsequently proposes this settlement to reaffirm that we stand along with Azerbaijan’s thalassemia middle and its individuals.”
Zhiyu Peng, BGI Genomics vice chairman
Mr Jeremy Cao, the Vice President of BGI IntDx, mentioned on the signing ceremony, “That is one in every of our pioneer abroad thalassemia tasks and such settlement commits us to work collectively extra carefully in direction of widespread targets, the pursuit of screening and management of thalassemia, and the imaginative and prescient that in a not too distant future there can be a world with out this illness. I want to say I’m assured that by our efforts and dedication, we will obtain extra and to proceed to develop even stronger relationships and friendships between the individuals of Azerbaijan and BGI.”
Thalassemia, an inherited blood dysfunction, brought on by the inadequate manufacturing of hemoglobin within the crimson blood cells that ship oxygen and vitamins to all components of the physique. Individuals with thalassemia have a lot much less hemoglobin than regular individuals and normally undergo from gentle to extreme anemia.
The Azerbaijan Thalassemia Middle is the primary main public medical establishments preventing thalassemia within the area. This Middle not solely offers service for sufferers that suffer from this illness but additionally for individuals with different genetic circumstances. The nation additionally affords a basis offering medical companies to overseas residents at this Middle.